港股异动|锦欣生殖涨逾5%获多家大行唱好
格隆汇8月6日丨锦欣生殖(1951.HK)逆势走强,现报9.08港元,涨幅5.46%,暂成交8257万港元,最新总市值216.2亿港元。瑞信研报指,估计潜在的中国辅助生殖服务市场规模约294亿美元,是去年实际市场规模38亿美元约8倍,在生育率不足,以及可负担的情况增加下,相信辅助生殖服务可受惠。同时,公司目前有关项目仍在发展阶段,潜力巨大,且入门门槛高,行业竞争者有限。首予其“跑赢大市”评级及公司12.25港元目标价。而摩根士丹利预计,公司2018至2021年收入及经调纯利的年复合增长率分别为40%及56%,首予其“增持”评级,目标价11港元。香港招商证券首次给予锦欣生殖买入评级,目标价11.1港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.